AG

Alex Gorsky

North America, New Jersey, United States, New Brunswick

Description

Alex Gorsky former Chairman and CEO of Johnson & Johnson. He attended The Wharton School.

Investor Profile

Alex Gorsky has made 2 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series E (50%)
  • Series B (50%)

Country Focus

  • United States (50%)
  • United Kingdom (50%)

Industry Focus

  • Life Science
  • Pharmaceutical
  • Biopharma
  • Biotechnology
  • Health Care
  • Precision Medicine
  • Artificial Intelligence (Ai)
  • Semantic Search
  • Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Alex Gorsky frequently co-invest with?

Farallon Capital Management
North America, California, United States, San Francisco
Co-Investments: 1
CA
North America, Massachusetts, United States, Boston
Co-Investments: 1
Catalio Capital Management
North America, New York, United States, New York
Co-Investments: 1
General Catalyst
North America, Massachusetts, United States, Cambridge
Co-Investments: 1
Google Ventures
North America, California, United States, Mountain View
Co-Investments: 1
Marshall Wace
Europe, England, United Kingdom, London
Co-Investments: 1
Foresite Capital
North America, California, United States, San Francisco
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 1
ARCH Venture Partners
North America, Illinois, United States, Chicago
Co-Investments: 1
Fidelity
North America, Massachusetts, United States, Boston
Co-Investments: 1

Which angels does Alex Gorsky often collaborate with?

OP
North America, New York, United States, New York
Shared Deals: 1

What are some of recent deals done by Alex Gorsky?

FogPharma

Cambridge, Massachusetts, United States

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

BiopharmaBiotechnologyHealth CareLife SciencePharmaceuticalPrecision Medicine
Series EMar 1, 2024
Amount Raised: $145,000,000
Causaly

London, England, United Kingdom

Causaly develops a biomedical research discovery tool designed to find and unlock key hidden evidence in biomedicine.

Artificial Intelligence (AI)Life SciencePharmaceuticalSemantic SearchSoftware
Series BJul 13, 2023
Amount Raised: $60,000,000